Market closedNon-fractional
Reviva Pharmaceuticals/RVPH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Reviva Pharmaceuticals
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.
Ticker
RVPH
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
Cupertino, United States
Employees
15
Website
www.revivapharma.com
RVPH Metrics
BasicAdvanced
$35M
Market cap
-
P/E ratio
-$1.54
EPS
0.05
Beta
-
Dividend rate
Price and volume
Market cap
$35M
Beta
0.05
Financial strength
Current ratio
0.931
Quick ratio
0.826
Total debt to equity
-24.669
Management effectiveness
Return on assets (TTM)
-191.50%
Return on equity (TTM)
-1,795.06%
Valuation
Price to book
-24.12
Price to tangible book (TTM)
-24.12
Price to free cash flow (TTM)
-0.941
Growth
Earnings per share change (TTM)
13.25%
3-year earnings per share growth
21.92%
What the Analysts think about RVPH
Analyst Ratings
Majority rating from 5 analysts.
RVPH Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$7.4M
-23.71%
Profit margin
0.00%
NaN%
RVPH Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.55
-$0.44
-$0.35
-$0.25
-
Expected
-$0.28
-$0.37
-$0.35
-$0.38
-$0.28
Surprise
99.28%
20.22%
-0.71%
-33.63%
-
RVPH News
AllArticlesVideos
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH
Accesswire·1 month ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH
PRNewsWire·1 month ago
Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Reviva Pharmaceuticals stock?
Reviva Pharmaceuticals (RVPH) has a market cap of $35M as of July 06, 2024.
What is the P/E ratio for Reviva Pharmaceuticals stock?
The price to earnings (P/E) ratio for Reviva Pharmaceuticals (RVPH) stock is 0 as of July 06, 2024.
Does Reviva Pharmaceuticals stock pay dividends?
No, Reviva Pharmaceuticals (RVPH) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Reviva Pharmaceuticals dividend payment date?
Reviva Pharmaceuticals (RVPH) stock does not pay dividends to its shareholders.
What is the beta indicator for Reviva Pharmaceuticals?
Reviva Pharmaceuticals (RVPH) has a beta rating of 0.05. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Reviva Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.